In this issue:
Tarlatamab in SCLC after platinum-based chemotherapy
Zongertinib in previously treated HER2-mutated NSCLC
Perioperative durvalumab, chemotherapy plus new agents for resectable NSCLC
Neoadjuvant nivolumab and platinum chemotherapy for locally advanced resectable NSCLC
Selpercatinib in RET fusion-positive NSCLC
Neoadjuvant osimertinib for resectable EGFR-mutated NSCLC
OS with neoadjuvant nivolumab + chemotherapy in lung cancer
Low-dose CT for lung cancer screening in a high-risk population
Bevacizumab and carboplatinpemetrexed ± atezolizumab for advanced pleural mesothelioma
Taletrectinib in ROS1+ NSCLC
Please login below to download this issue (PDF)